David Endicott joined Alcon as Chief Operating Officer, effective July 11, 2016, and is a member of the Alcon Executive Leadership Team. Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. Prior to the acquisition by Pfizer in 2015, Mr. Endicott led Hospira’s medical device business through a turnaround that advanced the company’s product pipeline, returned its products to market and accelerated global growth. Before joining Hospira, David served as an officer and executive committee member of Allergan where he spent 27 years of his career in commercial leadership roles across Asia and Latin America, Europe, Africa and Middle East, as well as the US, expanding Allergan’s international presence and successfully building new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and neurology. David holds an undergraduate degree in Chemistry from Whitman College, an MBA from the University of Southern California, and is a graduate of the Advanced Management Program at the Harvard Business School.

 Successfully building new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and neurology